Skip to main content
MyDeficiencies

Docusate

anionic surfactant stool softener (A06AA)

Also sold as Colace.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Docusate has no established classical depletion machinery. The references retrieved describe it as minimally absorbed and acting locally as an anionic surfactant [3][4], and the two OTC labels retrieved contain no pharmacokinetic section and no nutrient statement beyond avoiding mineral oil [1][2]. No Tier A study with docusate in the cohort that directly measured any nutrient or any of the seven physiological categories was retrieved, so the red and orange tiers are empty.

anionic surfactant stool softener (A06AA) · ATC A06AA02 · also sold as Colace; many OTC generics · reviewed 2026-10-04. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Docusate in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Magnesium: single case report, prolonged use in pregnancy

Yellow — Low

Evidence in: Tier B

One case report links low magnesium to prolonged docusate use during pregnancy, with normalization after stopping. It is reported secondhand and there are no cohort data.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, Tier B

Limits on what this shows

  • Key null findings: Dechallenge resolution is reported; no rechallenge is reported. No docusate study with magnesium as a measured outcome was otherwise retrieved. The OTC labels retrieved do not mention magnesium.
  • At-risk subgroups: The report concerns prolonged heavy use in pregnancy. No other subgroup is defined.

Regulatory status

No magnesium statement in the label fields retrieved (the tool returned truncated fields) [1][2].

Population evidence

Case-report level. The Drugs.com adverse-effects page states hypomagnesemia in one woman who took docusate chronically throughout her pregnancy, with magnesium levels returning to normal after docusate was discontinued [6]. Its reference list names Schindler AM, Lancet 1984;2:822, titled 'Isolated neonatal hypomagnesaemia associated with maternal overuse of stool softener'. The primary article could not be opened, so whether the low level was in the mother or the neonate, the values, the dose and the product could not be verified. No cohort, no effect estimate, no confidence interval.

Mechanism

Not stated in the retrieved text. No mechanism is claimed here.

Counter-evidence held on record

Counter-evidence on record One report cannot separate drug effect from maternal diet, other medicines, other laxatives or the constipation itself; confounding by indication is presumed until excluded (Hard Rule 6). The citation is secondhand, so the evidence tier is Tier B on the strength of the report type, pending reading of the primary article. Framing caution This is a low-level disturbance linked to overuse in one report. It is not a reason to take magnesium, and no dose is given anywhere in this dossier. Any magnesium decision belongs with a prescriber.

Potassium and fluid: dose-dependent loss with chronic overuse (context flag)

Yellow — Low

Evidence in: Tier B

A professional monograph cautions that chronic use may produce persistent diarrhea, hypokalemia, loss of essential nutritional factors and dehydration. No docusate study measuring potassium was retrieved.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, Tier B

Limits on what this shows

  • Key null findings: The same monograph describes adverse effects as rare, with occasional mild, transitory cramping, diarrhea or rash [4]. In the passages retrieved from the Drugs.com side-effects page, only hypomagnesemia was reported and hypokalemia was not [6].
  • At-risk subgroups: People with persistent diarrhea from high-dose or prolonged use; people on other potassium-lowering drugs (dichlorphenamide is the one named in [3]).

Regulatory status

Not found in the OTC label fields retrieved [1][2]. The Drugs.com professional monograph carries the chronic-use caution [4]. The PDR summary says docusate may be used cautiously with dichlorphenamide because of hypokalemia risk [3].

Population evidence

None. The caution is reference-text only, with no primary citation visible in the retrieved text, no design, no sample size and no effect estimate. This is the weakest basis that still qualifies as Tier B (established pharmacology reference). The wording is a generic chronic-laxative caution, so its docusate specificity is unverified.

Mechanism

Persistent diarrhea and dehydration after excess dosing. The monograph describes docusate as stimulating colonic water and electrolyte secretion [4], so this follows from the intended pharmacology when overdone (Hard Rule 2) and is filed as a context flag, not as a depletion mechanism at labeled doses. Additive potassium-lowering drugs are named in [3].

Counter-evidence held on record

Counter-evidence on record Co-use of other laxatives, diuretics and opioids, and the underlying constipation population, are not separated in any retrieved source (Hard Rule 6). No potassium measurement with docusate exposure was found. Framing caution This is a fluid and electrolyte loss disturbance tied to overuse, not a dietary shortfall. It is not an instruction to increase potassium intake, and no dose is given. Persistent diarrhea warrants clinician review.

Fat-soluble vitamin absorption (A, D, E, K) via surfactant action

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence that docusate changes absorption or status of vitamin A, D, E or K. This is a disclosed gap, added beyond the seven required categories.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

  • Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to therapeutic oral docusate was found to support even a yellow grade, and no circulating claim for this category was located to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. No circulating docusate-specific claim about fat-soluble vitamins was located, but consumer-claim searching was cut short when the search budget ran out. Status: genuine gap on the channels that worked; partly tooling-limited.

Regulatory status

The two OTC labels retrieved (docusate sodium 100 mg, docusate calcium 240 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

No study measured any fat-soluble vitamin with docusate in the cohort. The only surfactant-related absorption statements retrieved run in the opposite direction for lipid-phase substances: increased GI absorption of mineral oil and a general statement that docusate may enhance absorption of many oral drugs [4][5]. Those are not vitamin outcomes and are not used as evidence either way. The gut microbiome study measured lipids in a simulated colon, not vitamins [7]. A PubMed listing 'docusate vitamin' returned 19 records; those resolved (a vitamin E reverse-micelle physical chemistry paper, a pharmacoepidemiology liver-injury screen, a pyridine membrane-interaction paper) were not about vitamin status, and the remainder were not individually resolved.

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'docusate vitamin': 19 records (author list only returned; 3 resolved via OpenAlex single-record lookups, all non-clinical). Europe PMC listing 'docusate AND (vitamin OR deficiency OR absorption)': 25 records, none on a fat-soluble vitamin outcome. One web search on fat-soluble vitamin absorption returned only generic drug-reference pages; the DrugBank page was opened and showed no pharmacokinetic or nutrient content. Network state this review: direct curl to PubMed eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar and DailyMed was refused by the proxy (403 on CONNECT). Through the fetch tool, PubMed search-listing pages worked intermittently (several 429, bot-check or blank pages); Europe PMC answered one query then returned 429 on every later query; Crossref and Semantic Scholar searches returned 429; OpenAlex single-record lookups by PMID worked, OpenAlex search returned 429; the first DailyMed page returned 429 and the openFDA label API was used instead; Unpaywall was not attempted; the web-search budget (200 of 200) ran out mid-review. See the access note under Sources.

Repair pass

Near-miss, not graded: the same rat study [13] reports localized damage to surface absorptive cells after dioctyl sodium sulfosuccinate 260 mg/kg, and a 1975 Gastroenterology paper on structure and function of rodent and human intestine (PMID 1150046) exists, but its abstract was null in OpenAlex and the publisher page was not readable, so its findings are unknown. Neither measured lipid, carotenoid or fat-soluble vitamin absorption or status, so applying them to vitamins A, D, E or K would be an inference the sources do not make; the dose in [13] is also far above the labeled human range. Other absorption-enhancement records seen by title (tetracycline, sulfonamides, phenolsulfonphthalein, insulin; Caco-2 and rat epithelium formulation studies) are drug or peptide permeability work, not vitamin outcomes. PubMed listings 'docusate fat absorption' and 'dioctyl sodium sulfosuccinate vitamin' returned 429 and were not retried, so a vitamin-specific search under the alternate name is unfinished. Result: no vitamin-specific evidence found; first item to retry on revision. Repair pass limits: the web-search budget was already exhausted (200 of 200), so no new web search was possible; PubMed listing pages and single-record OpenAlex lookups were the working channels. Several PubMed listings returned 429 or a reCAPTCHA page and were not retried, as the fetch tool asked; article-level PubMed pages returned no content. Re-check on revision.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with docusate in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on mitochondrial structure, membrane integrity, electron transport or biogenesis with docusate. This is a disclosed gap.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

  • Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to therapeutic oral docusate was found to support even a yellow grade, and no circulating claim for this category was located to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Status: genuine gap on the channels that worked; partly tooling-limited because Europe PMC, Crossref, Semantic Scholar, OpenAlex search and the 228-drug paper were not reachable. Re-check on revision.

Regulatory status

The two OTC labels retrieved (docusate sodium 100 mg, docusate calcium 240 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

PubMed and web-search results were screened by title and, where opened, by abstract. Nothing described docusate given to a mammal or human at therapeutic exposure with a mitochondrial endpoint. Excipient and reverse-micelle (AOT) chemistry hits were not used (Hard Rule 7).

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'docusate mitochondria': 0 results (clean zero). PubMed listing 'docusate OR dioctyl sulfosuccinate OR dioctyl sodium sulfosuccinate mitochondrial': 3 records, none relevant (anthrone synthesis, silver nanoparticle coatings, a MELAS case report). PubMed listing 'docusate energy metabolism': 31 records, first page all non-clinical. One web search on in vitro mitochondrial toxicity returned only generic mitotoxicity references and a regulatory registration page; none was docusate-specific. A 228-drug mitochondrial toxicity assay paper (Chem Res Toxicol 2018) could not be opened (403), so whether docusate was among its drugs is unknown. Europe PMC mitochondria queries: 429. Network state this review: direct curl to PubMed eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar and DailyMed was refused by the proxy (403 on CONNECT). Through the fetch tool, PubMed search-listing pages worked intermittently (several 429, bot-check or blank pages); Europe PMC answered one query then returned 429 on every later query; Crossref and Semantic Scholar searches returned 429; OpenAlex single-record lookups by PMID worked, OpenAlex search returned 429; the first DailyMed page returned 429 and the openFDA label API was used instead; Unpaywall was not attempted; the web-search budget (200 of 200) ran out mid-review. See the access note under Sources.

Repair pass

Re-search for mammalian or human-cell data (Tier B if drug-specific). PubMed listing 'dioctyl sulfosuccinate mitochondria': 0 results (second clean zero under the alternate name). PubMed listing 'docusate Caco-2': 10 records on page 1, all drug-delivery formulation work (hydrophobic ion pairing, self-emulsifying systems) with permeability endpoints and no mitochondrial endpoint; the record 15707745 (Int J Pharm, absorption-enhancement epithelial models) had a null abstract in OpenAlex and was not readable. PubMed listing 'docusate hepatotoxicity OR liver OR cytotoxicity': 10 records on page 1, none with a mitochondrial endpoint in mammalian cells; the rainbow trout liver cell line paper is aquatic and was excluded. 'dioctyl sulfosuccinate ATP' returned a reCAPTCHA page (inconclusive). Result: no mammalian or human-cell mitochondrial membrane potential, respiration or ROS study of docusate was found, so there is nothing to grade at Tier B. Repair pass limits: the web-search budget was already exhausted (200 of 200), so no new web search was possible; PubMed listing pages and single-record OpenAlex lookups were the working channels. Several PubMed listings returned 429 or a reCAPTCHA page and were not retried, as the fetch tool asked; article-level PubMed pages returned no content. Re-check on revision.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with docusate in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on systemic or tissue redox or antioxidant-capacity markers with oral docusate in mammals or humans. This is a disclosed gap.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

  • Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to therapeutic oral docusate was found to support even a yellow grade, and no circulating claim for this category was located to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Editorial note: if an editor judges the aquatic DOSS studies to be admissible Tier B evidence, this entry would move to yellow; that call was not made here because the exposure route, species and concentration do not model oral therapeutic use. Status: genuine gap for cohort-appropriate evidence; partly tooling-limited.

Regulatory status

The two OTC labels retrieved (docusate sodium 100 mg, docusate calcium 240 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

Only aquatic ecotoxicology was found: a zebrafish study of waterborne DOSS at 1 to 80 mg/L in embryos and adults reported deregulated antioxidant-system genes in gill tissue and micronuclei in erythrocytes [8]; a sheepshead minnow larval study of Corexit 9500 or its component DOSS was seen by title only (Aquat Toxicol 2018, PMID 29128660) and not opened. Neither involves oral therapeutic dosing in a mammal, so neither is cohort-appropriate; both were excluded rather than borrowed (Hard Rule 7, excipient and environmental literature).

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'docusate oxidative stress': 5 records (the minnow study plus reverse-micelle, nanoparticle and melatonin papers). One web search surfaced the zebrafish study, which was opened via its ScienceDirect abstract page. Europe PMC oxidative-stress queries: 429. Network state this review: direct curl to PubMed eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar and DailyMed was refused by the proxy (403 on CONNECT). Through the fetch tool, PubMed search-listing pages worked intermittently (several 429, bot-check or blank pages); Europe PMC answered one query then returned 429 on every later query; Crossref and Semantic Scholar searches returned 429; OpenAlex single-record lookups by PMID worked, OpenAlex search returned 429; the first DailyMed page returned 429 and the openFDA label API was used instead; Unpaywall was not attempted; the web-search budget (200 of 200) ran out mid-review. See the access note under Sources.

Repair pass

Aquatic re-evaluation: the zebrafish study [8] (waterborne DOSS 1 to 80 mg/L, whole embryos and adult gill tissue, gene expression and micronuclei) was reconsidered for Tier C. It was kept excluded because the species is a fish, the exposure is waterborne at direct gill contact and not oral, and the endpoints are gene-expression and genotoxicity readouts, so it does not model a person taking an oral softgel; even as Tier C its relevance to human use is judged too low to support a yellow grade. The sheepshead minnow Corexit study (PMID 29128660) stays unopened and unused. Mammalian re-search: PubMed listing 'dioctyl sulfosuccinate oxidative OR lipid peroxidation OR reactive oxygen' dropped the surfactant term in parsing (34,400 records) and was discarded as unusable; 'docusate hepatotoxicity OR liver OR cytotoxicity' (10 records) and 'docusate Caco-2' (10 records) contained no mammalian redox, ROS or lipid peroxidation endpoint with docusate. Result: no cohort-appropriate mammalian or human-cell redox data found. Repair pass limits: the web-search budget was already exhausted (200 of 200), so no new web search was possible; PubMed listing pages and single-record OpenAlex lookups were the working channels. Several PubMed listings returned 429 or a reCAPTCHA page and were not retried, as the fetch tool asked; article-level PubMed pages returned no content. Re-check on revision.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with docusate in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on copper absorption, status or ceruloplasmin with docusate. This is a disclosed gap.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

  • Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to therapeutic oral docusate was found to support even a yellow grade, and no circulating claim for this category was located to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Status: genuine gap on the PubMed channel; secondary channels were tooling-limited. Kept separate from Iron.

Regulatory status

The two OTC labels retrieved (docusate sodium 100 mg, docusate calcium 240 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

No record describing copper measured in docusate users or docusate-exposed animals.

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'docusate copper': 2 records, neither relevant (marine antifouling coatings; metal nanoparticle effects on bacteria): clean zero for relevant evidence. Europe PMC listing 'docusate AND (vitamin OR deficiency OR absorption)': 25 records, none on copper. Other Europe PMC queries: 429. Network state this review: direct curl to PubMed eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar and DailyMed was refused by the proxy (403 on CONNECT). Through the fetch tool, PubMed search-listing pages worked intermittently (several 429, bot-check or blank pages); Europe PMC answered one query then returned 429 on every later query; Crossref and Semantic Scholar searches returned 429; OpenAlex single-record lookups by PMID worked, OpenAlex search returned 429; the first DailyMed page returned 429 and the openFDA label API was used instead; Unpaywall was not attempted; the web-search budget (200 of 200) ran out mid-review. See the access note under Sources.

Repair pass

Repair re-search under the alternate name: PubMed listing 'dioctyl sulfosuccinate copper' returned a reCAPTCHA page (inconclusive, not counted as a zero). PubMed listing 'dioctyl sodium sulfosuccinate absorption' (72 records, first 10 read by title) contained no copper outcome; the Caco-2, rat intestine and hepatotoxicity listings (30 records screened by title) contained none either. Result: still no copper evidence for docusate. Repair pass limits: the web-search budget was already exhausted (200 of 200), so no new web search was possible; PubMed listing pages and single-record OpenAlex lookups were the working channels. Several PubMed listings returned 429 or a reCAPTCHA page and were not retried, as the fetch tool asked; article-level PubMed pages returned no content. Re-check on revision.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with docusate in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

Iron

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on iron absorption, ferritin or iron status with docusate. This is a disclosed gap.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

  • Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to therapeutic oral docusate was found to support even a yellow grade, and no circulating claim for this category was located to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Status: genuine gap on the PubMed channel with one inconclusive query; secondary channels tooling-limited. Kept separate from Copper.

Regulatory status

The two OTC labels retrieved (docusate sodium 100 mg, docusate calcium 240 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

Records found were surfactant biochemistry or unrelated to docusate exposure in people.

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'docusate iron': 7 records, none relevant (a mycobacterial heme-protein paper, a pharmacist charting service, AOT reverse-micelle ferritin work, a supplement label content survey, a forward-osmosis membrane paper, others). PubMed listing 'docusate anemia': blank page, inconclusive and not counted as a zero. Europe PMC listing 'docusate AND (vitamin OR deficiency OR absorption)': 25 records, none on iron. Other Europe PMC queries: 429. Network state this review: direct curl to PubMed eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar and DailyMed was refused by the proxy (403 on CONNECT). Through the fetch tool, PubMed search-listing pages worked intermittently (several 429, bot-check or blank pages); Europe PMC answered one query then returned 429 on every later query; Crossref and Semantic Scholar searches returned 429; OpenAlex single-record lookups by PMID worked, OpenAlex search returned 429; the first DailyMed page returned 429 and the openFDA label API was used instead; Unpaywall was not attempted; the web-search budget (200 of 200) ran out mid-review. See the access note under Sources.

Repair pass

Repair re-search under the alternate name: PubMed listing 'dioctyl sulfosuccinate iron absorption': 0 results (clean zero for that phrasing). PubMed listing 'dioctyl sodium sulfosuccinate absorption' (72 records, first 10 read by title) held drug-absorption studies (tetracycline, sulfonamides, phenolsulfonphthalein, insulin) and no iron outcome. Result: still no iron evidence for docusate; the tetracycline absorption record (PMID 2420386, Biopharm Drug Dispos 1986) is a drug interaction seen by title only and was not opened. Repair pass limits: the web-search budget was already exhausted (200 of 200), so no new web search was possible; PubMed listing pages and single-record OpenAlex lookups were the working channels. Several PubMed listings returned 429 or a reCAPTCHA page and were not retried, as the fetch tool asked; article-level PubMed pages returned no content. Re-check on revision.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with docusate in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

Evidence in: Tier B

In vitro only: docusate sodium at conventional stool-softener doses produced global lipid and metabolite dysregulation in a simulated human colon microbiome model. No human data and no composition data were retrieved.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, Tier B

Limits on what this shows

  • Key null findings: The retrieved abstract does not report 16S composition, diversity or short-chain fatty acid data, and it does not measure any nutrient. It cannot be used as evidence about vitamin or mineral status.
  • At-risk subgroups: None identified. Long-term users are the group the authors flag as unstudied.

Regulatory status

No microbiome statement in the label fields retrieved [1][2].

Population evidence

One in vitro study using the SHIME simulated gut system (proximal and distal colonic compartments) with nontargeted UHPLC-MS/MS and GC-EI-MS lipidomics and metabolomics, Chem Res Toxicol 2023 [7]. Docusate sodium was tested with glyphosate and PFOA. The abstract reports global dysregulation of lipids and metabolites with docusate at doses described as conventional prescription stool-softener doses, and only minor differences with glyphosate or PFOA at acceptable daily intake levels. Concentration, duration, replicate number, effect sizes and confidence intervals were not available in the text retrieved. Cohort test: this is docusate itself at therapeutic dose, so it is cohort-appropriate as Tier B mechanistic evidence, not a class extrapolation.

Mechanism

Not characterized. The authors refer to probable yet uncharacterized off-target effects and call for study of long-term docusate treatment [7].

Counter-evidence held on record

Counter-evidence on record No in vivo or human microbiome study of docusate was retrieved (PubMed listing for docusate with microbiome returned 4 records, one of them this study). Constipation itself is presumed to confound any future human comparison until excluded (Hard Rule 6). Findings for other surfactants or emulsifiers were not borrowed (Hard Rule 7). Framing caution This is a functional laboratory signal, not a nutrient deficiency and not evidence of dysbiosis in people. It does not support probiotic or supplement recommendations.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on hemoglobin, hematocrit, red-cell mass or tissue oxygen delivery with docusate. This is a disclosed gap.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

  • Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to therapeutic oral docusate was found to support even a yellow grade, and no circulating claim for this category was located to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Status: genuine gap with one inconclusive query; secondary channels tooling-limited. Kept separate from ATP production.

Regulatory status

The two OTC labels retrieved (docusate sodium 100 mg, docusate calcium 240 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

Hits were non-clinical: a hydrophobic ion pairing paper, a dinitrosyl-iron paper, an in vitro anionic-surfactant and methemoglobin paper seen by title only (Colloids Surf B 2011, PMID 21131182, not opened), and AOT catalase chemistry. None involves docusate exposure in people. The drug's intended stool-softening action is not an oxygen-delivery effect and is not graded here (Hard Rule 2).

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'docusate hemoglobin': 4 records, none clinical. PubMed listing 'docusate anemia': blank page, inconclusive. A combined 'hemoglobin OR anemia OR hematocrit' listing dropped the docusate term in parsing (338,640 records) and was discarded as unusable. Europe PMC queries: 429 after the first. Network state this review: direct curl to PubMed eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar and DailyMed was refused by the proxy (403 on CONNECT). Through the fetch tool, PubMed search-listing pages worked intermittently (several 429, bot-check or blank pages); Europe PMC answered one query then returned 429 on every later query; Crossref and Semantic Scholar searches returned 429; OpenAlex single-record lookups by PMID worked, OpenAlex search returned 429; the first DailyMed page returned 429 and the openFDA label API was used instead; Unpaywall was not attempted; the web-search budget (200 of 200) ran out mid-review. See the access note under Sources.

Repair pass

Repair re-search: PubMed listing 'dioctyl sulfosuccinate hemoglobin' returned 429 and was not retried. The 'dioctyl sodium sulfosuccinate absorption', 'docusate Caco-2', 'docusate rat intestine' and 'docusate hepatotoxicity OR liver OR cytotoxicity' listings (about 40 records screened by title) held no hemoglobin, hematocrit, red-cell or oxygen-delivery endpoint. Result: still no evidence for this category. Repair pass limits: the web-search budget was already exhausted (200 of 200), so no new web search was possible; PubMed listing pages and single-record OpenAlex lookups were the working channels. Several PubMed listings returned 429 or a reCAPTCHA page and were not retried, as the fetch tool asked; article-level PubMed pages returned no content. Re-check on revision.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with docusate in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

ATP production

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on mitochondrial ATP synthesis or cellular energy output with docusate. This is a disclosed gap.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

  • Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence cohort-appropriate to therapeutic oral docusate was found to support even a yellow grade, and no circulating claim for this category was located to rebut as white. This is a disclosed evidence gap, not a finding of safety and not a statement that no effect exists. Status: genuine gap with one inconclusive query; tooling-limited on secondary channels. Kept separate from Mitochondrial burden and Oxygen delivery/utilization.

Regulatory status

The two OTC labels retrieved (docusate sodium 100 mg, docusate calcium 240 mg) carry no statement on this category in the fields returned [1][2].

Evidence reviewed

Records for energy-related terms were reverse-micelle enzymology, ecotoxicology and nanomaterial papers. Nothing involved docusate exposure with an ATP or cellular-energy endpoint.

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'docusate ATP': blank page, inconclusive. PubMed listing 'docusate energy metabolism': 31 records, first page non-clinical. PubMed listing 'docusate mitochondria': 0 results. Europe PMC queries: 429. Network state this review: direct curl to PubMed eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar and DailyMed was refused by the proxy (403 on CONNECT). Through the fetch tool, PubMed search-listing pages worked intermittently (several 429, bot-check or blank pages); Europe PMC answered one query then returned 429 on every later query; Crossref and Semantic Scholar searches returned 429; OpenAlex single-record lookups by PMID worked, OpenAlex search returned 429; the first DailyMed page returned 429 and the openFDA label API was used instead; Unpaywall was not attempted; the web-search budget (200 of 200) ran out mid-review. See the access note under Sources.

Repair pass

Near-miss, not graded: a rat study opened through its OpenAlex abstract [13] gave dioctyl sodium sulfosuccinate 260 mg/kg and found decreased jejunal and colonic Na,K-ATPase activity, raised prostaglandin E2 and localized damage to surface absorptive cells, with cyclic AMP unchanged. Na,K-ATPase is an ATP-consuming ion pump, so lower activity is a transport-enzyme finding and not a measure of ATP synthesis or cellular energy output; ATP content, respiration and energy charge were not reported in the abstract. Labeling it ATP production would be a category error (Hard Rule 2 spirit), and the dose is far above the labeled human range. It is used only as mechanism context for the Potassium and fluid entry and is not counted toward this category. Further queries: 'dioctyl sulfosuccinate ATP' returned a reCAPTCHA page (inconclusive). Result: no ATP-synthesis or energy-output endpoint with docusate was found. Repair pass limits: the web-search budget was already exhausted (200 of 200), so no new web search was possible; PubMed listing pages and single-record OpenAlex lookups were the working channels. Several PubMed listings returned 429 or a reCAPTCHA page and were not retried, as the fetch tool asked; article-level PubMed pages returned no content. Re-check on revision.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with docusate in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Unspecified "loss of essential nutritional factors" (no nutrient named)

    Where it comes from: Chronic-use caution in the Drugs.com professional monograph for docusate salts, which pairs persistent diarrhea, hypokalemia and dehydration with this phrase [4]. The wording reads as generic laxative-class language.

    Why it fails: It names no nutrient and no measured marker, so it cannot be falsified (Hard Rule 3). No docusate study of any vitamin or mineral level was retrieved. The one named nutrient in the sentence, potassium, is graded separately as a yellow context flag. Published only as a rebuttal.

How the body handles this medication

Absorption site
Described as minimally absorbed and acting locally, with some systemic absorption in the duodenum and jejunum. A second monograph lists absorption as not determined but occurring to some extent in the duodenum and jejunum.[3] PDR; [4] Drugs.com monograph
Metabolism and CYP450
Neither OTC label retrieved has a pharmacokinetic section, and no CYP450 substrate, inducer or inhibitor data were retrieved for docusate. One StatPearls chapter states significant first-pass metabolism with active and inactive metabolites and high protein binding, with no primary citation in the retrieved text and not corroborated by [3][4]; treated here as unverified.[1][2] openFDA labels; [5] StatPearls
Elimination and accumulation
Route of elimination, unchanged excretion and accumulation in renal or hepatic impairment are not stated in any retrieved source. This is unknown, not absent.[1][2][3][4][5]
Mechanism and renal handling
Anionic surfactant with emulsifying and wetting properties; lowers oil-water surface tension of stool so water and lipids penetrate; monograph adds stimulation of colonic water and electrolyte secretion. Softening begins in 1 to 3 days. No renal tubular effect is described.[3] PDR; [4] Drugs.com monograph
Interactions
Labels: do not use with mineral oil unless told by a doctor. Monograph: increased GI absorption of mineral oil, potentiation of aspirin-induced mucosal damage, and possible enhanced absorption of many oral drugs. StatPearls: systemic lipid granuloma risk with mineral oil. PDR: hypokalemia caution with dichlorphenamide. No food or mineral interaction with direction and magnitude was retrieved.[1][2][3][4][5]
Regulatory identity
WHO ATC A06AA02 (docusate sodium, softeners and emollients), DDD 0.15 g oral. OTC labels retrieved: 100 mg sodium softgel (effective 2026-03-05) and 240 mg calcium softgel (effective 2024-06-25); labeled use is occasional constipation, with a bowel movement generally in 12 to 72 hours for the sodium product.[1][2][9]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Monitoring

    Labs, only if indicated

    Serum potassium and magnesium (with sodium and hydration status) are reasonable only when high-dose or prolonged use is accompanied by persistent diarrhea, or in a pregnancy with long-term heavy use. No routine screening is supported by the evidence retrieved. This is a monitoring prompt, not a deficiency claim.

  • Monitoring

    Interaction timing

    Labels say not to use docusate with mineral oil unless told by a doctor [1][2]. No separation interval for any nutrient or drug is stated in the retrieved sources, so none is given. Because docusate may enhance absorption of many oral drugs [4], a pharmacist review is sensible for narrow-therapeutic-index co-medicines.

  • Monitoring

    At-risk groups

    Pregnancy with prolonged use (one magnesium report) [6]; people on other potassium-lowering drugs [3]; older adults and opioid users, who are the usual constipation populations and carry their own electrolyte and intake risks that are not attributable to docusate. Renal impairment and pediatric nutrient effects: no data retrieved. Liquid products in neonates carry a benzyl alcohol warning [5].

  • Monitoring

    Confounders to keep in view

    Constipation itself, reduced intake, opioids, other laxatives and diuretics. Hard Rule 6 presumes confounding by indication, so low levels in a docusate user are not attributed to the drug without further evidence.

  • Monitoring

    Supplements

    No supplement dose appears anywhere in this dossier, so no upper-intake-level comparison applies. Nothing here supports adding potassium, magnesium, vitamins or probiotics because of docusate.

Overlap map, to prevent double counting

  • Magnesium

    Shares evidence with: Potassium and fluid

    Note: Both rest on drug-reference adverse-effect text (Drugs.com pages [4][6]) and on the same mechanism class, gastrointestinal fluid loss with overuse of the intended secretory action. Treat as one line of weak evidence, not two.

  • Potassium and fluid

    Shares evidence with: Fails verification: unspecified nutritional factors

    Note: Same monograph sentence [4]. The rebuttal covers the unnamed remainder of the sentence whose named part is graded yellow.

  • Mitochondrial burden

    Shares evidence with: ATP production; Oxygen delivery/utilization; Oxidative stress

    Note: No supporting source exists for any of these. They share the same null and non-clinical PubMed result sets (docusate mitochondria, energy metabolism, hemoglobin, oxidative stress) and the same excluded aquatic and reverse-micelle literature. The shared absence must not be counted as separate confirmations.

  • Oxidative stress

    Shares evidence with: Gut microbiome risk

    Note: Both touch DOSS literature from the environmental chemical field. [7] models therapeutic stool-softener dosing in a simulated human colon and is retained; [8] is waterborne aquatic exposure and is excluded.

  • ATP production; Fat-soluble vitamin absorption

    Shares evidence with: Potassium and fluid

    Note: The rat intestinal study [13] (Na,K-ATPase, prostaglandin E2, surface-cell damage) is mechanism context for the fluid-secretion effect described in the Potassium and fluid entry. It is a near-miss for ATP production and fat-soluble vitamin absorption and is not counted as evidence for either ungraded entry.

  • Copper

    Shares evidence with: Iron

    Note: Independent entries that happen to share the same search channels and the same absence of retrieved evidence. No shared source.

  • Gut microbiome risk

    Shares evidence with: Fat-soluble vitamin absorption

    Note: [7] reports lipid dysregulation in a simulated colon. It measures no vitamin and must not be counted toward fat-soluble vitamin absorption.

All references used above
  1. [1] openFDA drug label record, docusate sodium 100 mg softgel (OTC) — Regulatory label, Tier A. SPL set ID 025e03e0-e273-47ed-87f7-98e388abe047, effective 2026-03-05. Purpose stool softener; do not use with mineral oil; no pharmacokinetic section. Fields returned by the retrieval tool were partly truncated.
  2. [2] openFDA drug label record, docusate calcium 240 mg softgel (OTC) — Regulatory label, Tier A. SPL set ID 2791223a-7ac0-47e5-9a6a-4d9a02cfeb63, effective 2024-06-25. Same mineral oil warning; no pharmacokinetic or interaction section. Fields partly truncated.
  3. [3] PDR drug summary, Colace (docusate sodium) capsules — Established drug reference, Tier B. Minimal absorption, local action; mineral oil and dichlorphenamide notes.
  4. [4] Drugs.com, Docusate Salts Monograph for Professionals — Established drug reference, Tier B. Pharmacokinetics, mechanism, interactions, adverse effects, chronic-use caution. Primary citations behind the statements were not visible in the retrieved text.
  5. [5] Hannoodee S, Patel P, Annamaraju P. Docusate. StatPearls, 2023 update (NCBI Bookshelf NBK555942) — Narrative reference, Tier B/C. Claims first-pass metabolism and mineral oil lipid granuloma risk; no vitamin, mineral or electrolyte interaction discussed.Metabolism statement uncorroborated by [3][4]; treated as unverified.
  6. [6] Drugs.com, Docusate Side Effects: Common, Severe, Long Term — Drug reference page, Tier B for the case it reports. Hypomagnesemia in one woman with chronic use in pregnancy, resolved after discontinuation; lists Schindler AM, Lancet 1984;2:822.Primary case report (Lancet 1984) not opened; cited only as reported by this page.
  7. [7] Aristizabal-Henao JJ, Bowden JA. Novel in vitro intestinal microbiome model to study lipidomic and metabolomic adaptations due to exposure to glyphosate, PFOA and docusate sodium. Chem Res Toxicol 2023 — In vitro SHIME model, docusate sodium at stool-softener doses; DOI 10.1021/acs.chemrestox.3c00091; PMID 37342084. Abstract read on the ACS landing page and via the OpenAlex record (https://api.openalex.org/works/pmid:37342084). Docusate in the studied exposure: yes.Full text and supporting information not opened; concentration, duration and replicate details unavailable.
  8. [8] Gonzalez-Penagos CE, Zamora-Briseno JA, Amendola-Pimenta M, et al. The surfactant dioctyl sodium sulfosuccinate (DOSS) exposure causes adverse effects in embryos and adults of zebrafish. Toxicol Appl Pharmacol 2022;443 — Aquatic ecotoxicology, waterborne DOSS 1 to 80 mg/L. Abstract page read. Docusate (DOSS) was the test substance but not at oral therapeutic exposure.Excluded from grading: not cohort-appropriate to therapeutic oral use (see Oxidative stress).
  9. [9] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, A06AA02 — Classification: docusate sodium, DDD 0.15 g oral.
  10. [10] PubMed search-listing pages queried 2026-10-04 — Queries: docusate (986 records, first page read); docusate microbiome; docusate oxidative stress; docusate mitochondria; docusate OR dioctyl sulfosuccinate OR dioctyl sodium sulfosuccinate mitochondrial; docusate iron; docusate copper; docusate vitamin; docusate magnesium; docusate potassium; docusate hemoglobin; docusate energy metabolism. Blank, bot-check or inconclusive pages: docusate anemia, docusate ATP, docusate hypokalemia, docusate hypomagnesemia, hypomagnesemia docusate pregnancy, and a title search for the Lancet 1984 report.Listings screened by title; individual records were not opened except where stated in an entry. Article pages returned reCAPTCHA or blank content.
  11. [11] Europe PMC REST search, 'docusate AND (vitamin OR deficiency OR absorption)', 25 records returned — One query answered; none of the 25 records concerned a docusate nutrient outcome. Later Europe PMC queries returned 429.
  12. [12] Saunders DR, Sillery J, Rachmilewitz D. Effect of dioctyl sodium sulfosuccinate on structure and function of rodent and human intestine. Gastroenterology 1975 — Bibliographic record only (OpenAlex); abstract null; publisher page returned 403. Relevant to mechanism class A (mucosal effects) but not read.Could not be opened; not used for any grade.
  13. [13] Effect of dioctyl sodium sulfosuccinate on cyclic AMP and prostaglandin E2 contents, and Na,K-ATPase, adenylate cyclase and phosphodiesterase activities in rat intestine. Isr J Med Sci 1981 (PMID 6161903) — Rat in vivo mechanistic study, Tier B, docusate (dioctyl sodium sulfosuccinate) as the test substance at 260 mg/kg. Abstract read through the OpenAlex record (https://api.openalex.org/works/pmid:6161903): decreased jejunal and colonic Na,K-ATPase, raised prostaglandin E2, localized damage to surface absorptive cells, cyclic AMP unchanged. Used as mechanism context and as a documented near-miss only; no nutrient or the seven categories were measured.Full text not opened; sample size, doses other than 260 mg/kg and effect sizes unavailable.
  14. [14] Repair-pass retrieval log, 2026-10-04: PubMed listings and OpenAlex single-record lookups — PubMed listings read: dioctyl sulfosuccinate mitochondria (0); docusate Caco-2 (10 on page 1); docusate rat intestine (10); dioctyl sodium sulfosuccinate absorption (72 total, 10 read); docusate hepatotoxicity OR liver OR cytotoxicity (10); dioctyl sulfosuccinate iron absorption (0). Unusable or blocked: dioctyl sulfosuccinate oxidative OR lipid peroxidation OR reactive oxygen (term dropped); docusate fat absorption, dioctyl sodium sulfosuccinate intestine, dioctyl sodium sulfosuccinate vitamin, dioctyl sulfosuccinate hemoglobin (429, not retried); dioctyl sulfosuccinate copper and dioctyl sulfosuccinate ATP (reCAPTCHA). OpenAlex lookups with null abstracts: PMID 15707745, 11745735, 1150046 and 170157 (Saunders 1975 colonic fluid and electrolyte movement). Records seen by title only and not used: LiverTox docusate (PMID 31643530), HSV preclinical docusate (PMID 11530185), rainbow trout liver cells (PMID 28802573), tetracycline absorption (PMID 2420386).Listings screened by title; not used for any grade.